/https%3A%2F%2Fsportsmole-media-prod.s3.gra.io.cloud.ovh.net%2Fuploads%2F2026%2F01%2Framsay-1-69715c39b7a89799742767.jpg?ssl=1 "Preview: West Bromwich Albion vs Coventry City – prediction, team news, lineups")
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adoption of its core endocrinology products. Q4 was particularly significant, as the company achieved an operating profit of €10 million and generated €73 million in operating cash flow. This was largely driven by YORVIPATH, which brought in €477 million for the full year, and the steady performance of SKYTROFA, which contributed €206 million.
Despite a full-year net loss of €228 million due to commercial investments, the company ended the year with a solid cash position of €616 million, supported by a $100 million partnership payment from Novo Nordisk. The company’s success is rooted in its proprietary TransCon tech platform, which transforms established drugs into long-acting, once-weekly prodrugs. By linking parent drugs to an inert carrier via a temporary linker, TransCon ensures a predictable and sustained release of the active medication.
15 States with the Best Healthcare in the US
This has allowed Ascendis Pharma (NASDAQ:ASND) to secure a dominant 45% share of the US long-acting growth hormone market for SKYTROFA. Management is now preparing for the next major growth phase with the anticipated FDA approval of TransCon CNP for pediatric achondroplasia, which has a PDUFA action date of February 28, 2026, and is expected to provide a new therapeutic option beyond simple linear growth.
Ascendis Pharma (NASDAQ:ASND) is a biopharmaceutical company that develops TransCon-based (Transient Conjugation) therapies for unmet medical needs in Europe, the US, and internationally.
While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
